Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer

Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer Publisher

Eslami B¹ ; Alipour S^{1, 2} ; Golfam F³ ; Jahabnin B⁴ ; Omranipour R^{1, 5}

Show Affiliations

1. Breast Diseases Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Surgery, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Mostafa Khomeini Hospital, Shahed University, Tehran, Iran
4. Department of Pathology Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Pathology Published:2024

Abstract

Background & Objective: Antigen Ki-67 (histone-based nuclear protein) is a static marker of tumor cell proliferation and growth and is commonly measured to indicate the effect of treatment in breast cancer patients. This single-arm trial study aimed to evaluate the effect of short-term endocrine therapy (letrozole) on Ki-67 levels in menopausal women with early hormone-positive breast cancer who were referred to two university hospitals. Methods: Patients with a pre-treatment Ki67 of 5% or less were excluded from the study. Participants (n=25) received oral letrozole (2.5 mg daily) seven days before surgery. Ki-67% on both biopsies and the surgical specimens were measured and compared. Results and Conclusion: The mean age of patients was 62±9.4 (48-83 years). Our result indicated that pre-surgery consumption of letrozole for hormone-positive breast cancer can significantly decrease the of Ki-67 labeling index (23.24±9.74 vs. 16.92±9.55, P=0.001 by paired t-test), with no drug-related adverse events. This study was carried out according to the World Medical Association Declaration of Helsinki, and the ethics committee of Tehran University of Medical Sciences approved it (IR.TUMS.VCR.REC.1398.966). Informed consent was obtained from all participants. © 2024, Iranian Society of Pathology. All rights reserved.

Style	Citing Format
MLA	Eslami B, et al.. "Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer." Iranian Journal of Pathology, vol. 19, no. 1, 2024, pp. 103-106.
APA	Eslami B, Alipour S, Golfam F, Jahabnin B, Omranipour R (2024). Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer. Iranian Journal of Pathology, 19(1), 103-106.
Chicago	Eslami B, Alipour S, Golfam F, Jahabnin B, Omranipour R. "Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer." Iranian Journal of Pathology 19, no. 1 (2024): 103-106.
Harvard	Eslami B et al. (2024) 'Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer', Iranian Journal of Pathology, 19(1), pp. 103-106.
Vancouver	Eslami B, Alipour S, Golfam F, Jahabnin B, Omranipour R. Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer. Iranian Journal of Pathology. 2024;19(1):103-106.
BibTex	@article{ author = {Eslami B and Alipour S and Golfam F and Jahabnin B and Omranipour R}, title = {Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer}, journal = {Iranian Journal of Pathology}, volume = {19}, number = {1}, pages = {103-106}, year = {2024} }
RIS	TY - JOUR AU - Eslami B AU - Alipour S AU - Golfam F AU - Jahabnin B AU - Omranipour R TI - Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer JO - Iranian Journal of Pathology VL - 19 IS - 1 SP - 103 EP - 106 PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract